Search

Your search keyword '"Pang, Gavin"' showing total 18 results
Start Over Author "Pang, Gavin"
18 results on '"Pang, Gavin"'

1. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Author

Yong, Kwee, Wilson, William, de Tute, Ruth M, Camilleri, Marquita, Ramasamy, Karthik, Streetly, Matthew, Sive, Jonathan, Bygrave, Ceri A, Benjamin, Reuben, Chapman, Michael, Chavda, Selina J, Phillips, Elizabeth H, del Mar Cuadrado, Maria, Pang, Gavin, Jenner, Richard, Dadaga, Tushhar, Kamora, Sumaiya, Cavenagh, James, Clifton-Hadley, Laura, Owen, Roger G, and Popat, Rakesh

Published
2023
Full Text
View/download PDF

2. Machine learning from the CARDAMON trial identifies a carfilzomib-specific mutational response signature

Author

Walker, Ieuan G, primary, D'Arcy, Venetia, additional, Khandelwal, Garima Khandelwal, additional, Anderson, Georgina, additional, Aubareda, Anna, additional, Wilson, William, additional, Fitzsimons, Evelyn, additional, Galas-Filipowicz, Daria, additional, Foster, Kane, additional, Popat, Rakesh Popat, additional, Ramasamy, Karthik, additional, Streetly, Matthew, additional, Bygrave, Ceri, additional, Benjamin, Reuben, additional, de Tute, Ruth M, additional, Camilleri, Marquita, additional, Chavda, Selina J, additional, Pang, Gavin, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, Cavenagh, James, additional, Phillips, Elizabeth H, additional, Clifton-Hadley, Laura, additional, Owen, Roger G, additional, Herrero, Javier Herrero, additional, Yong, Kwee, additional, and Chapman, Michael A, additional

Published
2023
Full Text
View/download PDF

3. Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Author

Popat, Rakesh, primary, Wilson, William, additional, Camilleri, Marquita, additional, Ramasamy, Karthik, additional, Streetly, Matthew, additional, Sive, Jonathan, additional, Bygrave, Ceri, additional, Benjamin, Reuben, additional, Chapman, Michael A, additional, Chavda, Selina J, additional, Phillips, Beth, additional, Cuadrado, Maria del Mar, additional, Pang, Gavin, additional, Jenner, Richard, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, de Tute, Ruth M., additional, Cavenagh, James, additional, Clifton-Hadley, Laura, additional, Owen, Roger G, additional, and Yong, Kwee, additional

Published
2022
Full Text
View/download PDF

4. Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Author

Walker, Ieuan, primary, D'arcy, Venetia, additional, Rodriguez Romera, Antonio, additional, Anderson, Georgina, additional, Aubareda, Anna, additional, Roy, James, additional, Khandelwal, Garima, additional, Wilson, William, additional, Fitzsimons, Evelyn, additional, Galas-Filipowicz, Daria, additional, Foster, Kane, additional, Popat, Rakesh, additional, Ramasamy, Karthik, additional, Streetly, Matthew, additional, Bygrave, Ceri, additional, Benjamin, Reuben, additional, de Tute, Ruth M., additional, Camilleri, Marquita, additional, Chavda, Selina J, additional, Pang, Gavin, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, Cavenagh, James, additional, Phillips, Elizabeth H., additional, Clifton-Hadley, Laura, additional, Owen, Roger G, additional, Herrero, Javier, additional, Yong, Kwee, additional, and Chapman, Michael A, additional

Published
2022
Full Text
View/download PDF

5. P-228: ASCT does not benefit patients who are MRD negative following induction therapy: updated results from the Phase 2 Cardamon study

Author

Yong, Kwee, primary, Wilson, William, additional, de Tute, Ruth, additional, Camilleri, Marquita, additional, Ramasamy, Karthik, additional, Streetly, Matthew, additional, Sive, Jonathan, additional, Bygrave, Ceri, additional, Benjamin, Reuben, additional, Chapman, Michael, additional, Chavda, Selina, additional, Philips, Elizabeth, additional, del Mar Cuadrado, Maria, additional, Pang, Gavin, additional, Jenner, Richard, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, Cavenagh, James, additional, Clifton-Hadley, Laura, additional, Owen, Roger, additional, and Popat, Rakesh, additional

Published
2022
Full Text
View/download PDF

6. OAB-018: From CARDAMON to CoMMpass: a mutational signature that predicts carfilzomib-specific outcomes in myeloma

Author

Walker, Ieuan, primary, Khandelwal, Garima, additional, D’Arcy, Venetia, additional, Wilson, William, additional, Fitzsimons, Evie, additional, Galas-Filipowicz, Daria, additional, Popat, Rakesh, additional, Ramasamy, Karthik, additional, Streetly, Matthew, additional, Bygrave, Ceri, additional, Benjamin, Reuben, additional, de Tute, Ruth, additional, Camilleri, Marquita, additional, Chavda, Selina, additional, Pang, Gavin, additional, Jenner, Richard, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, Cavenagh, James, additional, Clifton-Hadley, Laura, additional, Owen, Roger, additional, Herrero, Javier, additional, Yong, Kwee, additional, and Chapman, Michael, additional

Published
2022
Full Text
View/download PDF

7. P-084: Bone marrow of patients post ASCT, but not chemotherapy consolidation, contains expanded T cell receptor clonotypes that are present at diagnosis: results from the Phase 2 CARDAMON study

Author

Foster, Kane, primary, Galas-Filipowicz, Daria, additional, Fitzsimons, Evie, additional, Wilson, William, additional, Lee, Lydia, additional, Byrne, Suzanne, additional, Ramasamy, Karthik, additional, Popat, Rakesh, additional, Chapman, Michael, additional, Streetly, Matthew, additional, Bygrave, Ceri, additional, Benjamin, Reuben, additional, de Tute, Ruth, additional, Camilleri, Marquita, additional, Chavda, Selina, additional, Philips, Elizabeth, additional, Pang, Gavin, additional, Jenner, Richard, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, Cavenagh, James, additional, Clifton-Hadley, Laura, additional, Owen, Roger, additional, Chain, Benny, additional, and Yong, Kwee, additional

Published
2022
Full Text
View/download PDF

8. Upfront Autologous Stem Cell Transplantation (ASCT) vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation with K Maintenance in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Phase 2 Non-Inferiority Cardamon Study

Author

Yong, Kwee, primary, Wilson, William, additional, de Tute, Ruth M., additional, Camilleri, Marquita, additional, Ramasamy, Karthik, additional, Streetly, Matthew, additional, Sive, Jonathan, additional, Bygrave, Ceri A., additional, Benjamin, Reuben, additional, Chapman, Michael, additional, Chavda, Selina J., additional, Phillips, Elizabeth H., additional, Cuadrado, Maria del Mar, additional, Pang, Gavin, additional, Jenner, Richard, additional, Dadaga, Tushar, additional, Kamora, Sumaiya, additional, Cavenagh, James, additional, Clifton-Hadley, Laura, additional, Owen, Roger G., additional, and Popat, Rakesh, additional

Published
2022
Full Text
View/download PDF

9. Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk

Author

Yong, Kwee, primary, Wilson, William, additional, Camilleri, Marquita, additional, Ramasamy, Karthik, additional, Streetly, Matthew, additional, Sive, Jonathan, additional, Bygrave, Ceri A, additional, Chapman, Michael, additional, de Tute, Ruth M., additional, Chavda, Selina J, additional, Phillips, Elizabeth H, additional, Cuadrado, Maria del Mar, additional, Pang, Gavin, additional, Jenner, Richard, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, Cavenagh, James, additional, Clifton-Hadley, Laura, additional, Owen, Roger G, additional, and Popat, Rakesh, additional

Published
2021
Full Text
View/download PDF

10. PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

Author

Bygrave, Ceri A, primary, Subesinghe, Manil, additional, Wilson, William, additional, Popat, Rakesh, additional, Ramasamy, Karthik, additional, Pang, Gavin, additional, Jenner, Richard, additional, Kamora, Sumaiya, additional, Dadaga, Tushhar, additional, Pike, Lucy, additional, Streetly, Matthew, additional, Camilleri, Marquita, additional, Owen, Roger G, additional, Cavenagh, James, additional, Sive, Jonathan, additional, Chapman, Michael, additional, Phillips, Elizabeth H, additional, Chavda, Selina J, additional, Cuadrado, Maria del Mar, additional, Benjamin, Reuben, additional, Eccersley, Lydia, additional, Moore, Sally, additional, Banerjee, Lalita, additional, Clifton-Hadley, Laura, additional, Barrington, Sally F, additional, and Yong, Kwee, additional

Published
2021
Full Text
View/download PDF

11. OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

Author

Popat, Rakesh, primary, Wilson, William, additional, Camilleri, Marquita, additional, Tute, Ruth De, additional, Pang, Gavin, additional, Jenner, Richard, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, Streetly, Matthew, additional, Ramasamy, Karthik, additional, Phillips, Elizabeth, additional, Chapman, Mike, additional, Bygrave, Ceri, additional, Cavenagh, James, additional, Sive, Jonathan, additional, Benjamin, Reuben, additional, Eccersley, Lydia, additional, Hassan, Sandra, additional, Willis, Fenella, additional, Clifton-Hadley, Laura, additional, Owen, Roger, additional, and Yong, Kwee, additional

Published
2021
Full Text
View/download PDF

12. P-390 The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON study

Author

Foster, Kane, Galas-Filipowicz, Daria, Fitzsimons, Evie, Wilson, William, Lee, Lydia, Byrne, Suzanne, Ramasamy, Karthik, Popat, Rakesh, Chapman, Mike, Streetly, Matthew, Bygrave, Ceri, Benjamin, Reuben, de Tute, Ruth, Camilleri, Marquita, Chavda, Selina, Philips, Elizabeth, Pang, Gavin, Fananapazir, Fu'ad, Parikh, Krupali, Kamora, Sumaiya, Cavenagh, James, Owen, Roger, Tyson, Charlotte, Chain, Benny, and Yong, Kwee

Published
2023
Full Text
View/download PDF

13. Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

Author

Yong, Kwee, primary, Camilleri, Marquita, additional, Wilson, William, additional, Ramasamy, Karthink, additional, Streetly, Matthew J., additional, Sive, Jonathan, additional, Bygrave, Ceri, additional, Chapman, Michael A, additional, De Tute, Ruth, additional, Chavda, Selina J, additional, Phillips, Elizabeth, additional, Cuadrado, Maria, additional, Pang, Gavin, additional, Jenner, Richard, additional, Dadaga, Tushhar, additional, Kamora, Sumaiya, additional, Cavenagh, James D., additional, Clifton-Hadley, Laura, additional, Owen, Roger G., additional, and Popat, Rakesh, additional

Published
2021
Full Text
View/download PDF

14. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study

Author

Camilleri, Marquita, primary, Cuadrado, Maria, additional, Phillips, Elizabeth, additional, Wilson, William, additional, Jenner, Richard, additional, Pang, Gavin, additional, Kamora, Sumaiya, additional, Streetly, Matthew, additional, Popat, Rakesh, additional, Bygrave, Ceri, additional, Owen, Roger, additional, Cavenagh, James, additional, Chapman, Mike, additional, Sive, Jonathan, additional, Eccersley, Lydia, additional, Sheaff, Michael, additional, Benjamin, Reuben, additional, Ramasamy, Karthik, additional, Cook, Gordon, additional, Virchis, Andres, additional, Chavda, Selina J., additional, Clifton‐Hadley, Laura, additional, Scully, Marie Anne, additional, and Yong, Kwee, additional

Published
2021
Full Text
View/download PDF

15. COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial

Author

Camilleri, Marquita, primary, Sive, Jonathan, additional, Wilson, William, additional, Pang, Gavin, additional, Jenner, Richard, additional, Phillips, Elizabeth, additional, Popat, Rakesh, additional, Ramasamy, Karthik, additional, Bygrave, Ceri, additional, Dadaga, Tushhar, additional, Streetly, Matthew, additional, Cavenagh, James, additional, Chapman, Mike, additional, Barrington, Sally, additional, Pike, Lucy, additional, Owen, Roger, additional, Clifton‐Hadley, Laura, additional, and Yong, Kwee, additional

Published
2020
Full Text
View/download PDF

16. Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Author

Yong, Kwee, primary, Popat, Rakesh, primary, Wilson, William, primary, Pang, Gavin, primary, Jenner, Richard, primary, De Tute, Ruth M, primary, Ramasamy, Karthik, primary, Streetly, Matthew, primary, Cavenagh, Jamie, primary, Sive, Jonathan, primary, Chapman, Michael, primary, Bygrave, Ceri, primary, Phillips, Beth, primary, Chavda, Selina J, primary, Virchis, Andres E., primary, Benjamin, Reuben, primary, Arnott, Sarah, primary, Willis, Fenella, primary, Hassan, Sandra, primary, Moore, Sally, primary, Clifton-Hadley, Laura, primary, and Owen, Roger G, primary

Published
2019
Full Text
View/download PDF

17. COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial.

Author

Camilleri, Marquita, Sive, Jonathan, Wilson, William, Pang, Gavin, Jenner, Richard, Phillips, Elizabeth, Popat, Rakesh, Ramasamy, Karthik, Bygrave, Ceri, Dadaga, Tushhar, Streetly, Matthew, Cavenagh, James, Chapman, Mike, Barrington, Sally, Pike, Lucy, Owen, Roger, Clifton‐Hadley, Laura, and Yong, Kwee

Subjects
COVID-19, CARDAMOMS, CLINICAL trials, COVID-19 pandemic
Abstract

Keywords: myeloma; COVID-19; clinical trials EN myeloma COVID-19 clinical trials e14 e16 3 12/21/20 20210101 NES 210101 COVID-19 - caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - has spread to over 213 countries and territories, with 24,021,218 cases, including 821,462 deaths, reported to WHO by 28 August 2020.1 In the UK alone, there were 328,846 laboratory-confirmed cases and 41,465 COVID-19-associated deaths.2 Self-isolation and physical distancing measures were implemented in most jurisdictions to limit the spread of the virus. PIs may be potentially biased to alter treatment based on local COVID-19 clusters and patients' favourable MM response. Therefore, sensitivity analyses will be performed with and without the inclusion of affected patients to assess the significance of the measures taken on patient outcomes. [Extracted from the article]

Published
2021
Full Text
View/download PDF

18. Efficacy and Safety of Carfilzomib at 56mg/m2with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Author

Yong, Kwee, Popat, Rakesh, Wilson, William, Pang, Gavin, Jenner, Richard, De Tute, Ruth M, Ramasamy, Karthik, Streetly, Matthew, Cavenagh, Jamie, Sive, Jonathan, Chapman, Michael, Bygrave, Ceri, Phillips, Beth, Chavda, Selina J, Virchis, Andres E., Benjamin, Reuben, Arnott, Sarah, Willis, Fenella, Hassan, Sandra, Moore, Sally, Clifton-Hadley, Laura, and Owen, Roger G

Abstract

Introduction:Carfilzomib (20/36mg/m2) triplets with Lenalidomide-Dexamethasone (KRd), or Cyclophosphamide-Dexamethasone (KCd) are safe and effective in patients with newly diagnosed multiple myeloma(NDMM). The higher dose of 56mg/m2is effective as a doublet with Dexamethasone in the relapsed setting, but there is limited data on this dose in triplet combinations in the frontline setting.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results